A Phase 3, Multi-centre, Randomised, Double-blind, Active-controlled, Parallel-group Trial Investigating the Efficacy and Safety of FE 999315 Following 8 Weeks of Treatment for Mild to Moderate Active Ulcerative Colitis in Japanese Subjects
A Phase 3, Multi-centre, Randomised, Double-blind, Active-controlled, Parallel-group Trial Investigating the Efficacy and Safety of FE 999315 Following 8 Weeks of Treatment for Mild to Moderate Active Ulcerative Colitis in Japanese Subjects
To demonstrate non-inferiority in efficacy of FE 999315 to mesalazine in patients with mild to moderate active ulcerative colitis after 8 weeks of treatment.
Inclusion Criteria:
Exclusion Criteria:
Toyoake-shi, Aichi-ken, Japan
Toyota-shi, Aichi-ken, Japan
Abiko-shi, Chiba, Japan
Kashiwa-shi, Chiba, Japan
Urayasu-shi, Chiba, Japan
Kitakyushu-shi, Fukuoka, Japan
Kitakyushu-shi, Fukuoka, Japan
Kitakyushu-shi, Fukuoka, Japan
Kurume-shi, Fukuoka, Japan
Takasaki-shi, Gunma, Japan
Asahikawa-shi, Hokkaido, Japan
Hakodate-shi, Hokkaido, Japan
Nishinomiya-shi, Hyōgo, Japan
Nishinomiya-shi, Hyōgo, Japan
Kasama-shi, Ibaraki, Japan
Koga-shi, Ibaraki, Japan
Tsuchiura-shi, Ibaraki, Japan
Nankoku-shi, Kochi, Japan
Yokkaichi-shi, Mie-ken, Japan
Beppu-shi, Oita Prefecture, Japan
Fujiidera-shi, Osaka, Japan
Sakai-shi, Osaka, Japan
Suita-shi, Osaka, Japan
Takatsuki-shi, Osaka, Japan
Toyonaka-shi, Osaka, Japan
Saitama-shi, Saitama, Japan
Saitama-shi, Saitama, Japan
Sakura-shi, Saitama, Japan
Tokorozawa-shi, Saitama, Japan
Tokorozawa-shi, Saitama, Japan
Fuchū-shi, Tokyo, Japan
Kodaira-shi, Tokyo, Japan
Machida-shi, Tokyo, Japan
Meguro-ku, Tokyo, Japan
Minato-ku, Tokyo, Japan
Mitaka-shi, Tokyo, Japan
Oume-shi, Tokyo, Japan
Shinagawa-Ku, Tokyo, Japan
Shinjuku-Ku, Tokyo, Japan
Hiroshima-shi, Hiroshima, Japan